HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $27.
August 06, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Enanta Pharma and maintained a price target of $27.
The reiteration of a Buy rating and the maintenance of a $27 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100